BE CAR-33

BE CAR-33 is an investigational allogeneic, "off-the-shelf" chimeric antigen receptor (CAR) T-cell therapy being developed for the treatment of relapsed or refractory acute myeloid leukemia (AML), particularly in pediatric populations. The therapy utilizes healthy donor-derived T-cells that are engineered to express a CAR targeting the **CD33** antigen, which is highly expressed on AML blasts. To overcome challenges inherent in targeting myeloid antigens and using allogeneic cells, BE CAR-33 is manufactured using CRISPR-mediated base editing. This precision genome editing technology is used to perform multiplex modifications, including the knockout of the **TRAC** gene (to prevent graft-versus-host disease) and the disruption of the endogenous **CD33** gene on the T-cells themselves (to prevent fratricide, or self-killing, of the CAR T-cells). This approach aims to provide a readily available cell product for patients who may not have time for autologous manufacturing, potentially serving as a bridge to a definitive stem cell transplant.

Other names

Base-Edited CD33 CAR T-cellsBase Edited CAR T Cells Against AML